生血宁片治疗维持性血液透析患者肾性贫血的临床观察

目的:观察生血宁片改善规律维持性血液透析尿毒症肾性贫血患者的铁代谢及其与促红细胞生成素协同作用的临床疗效.方法:选择我院血液净化中心规律维持性血液透析尿毒症肾性贫血患者60例为研究对象,随机分为生血宁组和琥珀酸亚铁组,每组30例.生血宁组口服生血宁片,琥珀酸亚铁组口服琥珀酸亚铁片.两组患者均按照肾性贫血治疗指南中建议剂量个体化联合应用促红细胞生成素治疗.16周后对两组患者进行临床疗效观察,详细记录治疗前和治疗后两组患者的血红蛋白、红细胞比容、血清铁蛋白、转铁蛋白饱和度等指标变化,同时监测两组患者治疗中出现的不良反应.结果:治疗16周后两组患者的血红蛋白、红细胞比容、血清铁蛋白、转铁蛋白饱和度与治疗前比较均有增高,差异具有统计学意义(P<0.05);但生血宁组治疗后血红蛋白、红细胞比容、血清铁蛋白、转铁蛋白饱和度明显高于琥珀酸亚铁组,差异具有统计学意义(P<0.05).与琥珀酸亚铁组比较,生血宁组不良反应发生较少.结论:与琥珀酸亚铁组比较,生血宁能更有效补充尿毒症肾性贫血患者所需的铁剂,且生血宁不良反应少,安全性好.

Clinical Observation of Shengxuening Tablets in the Treatment of Maintenance Hemodialysis Patients with Renal Anemia

Objective: To observe the clinical efficacy of Shengxuening tablets to improve the law to maintain iron metabolism in hemodialysis patients with renal anemia and erythropoietin and its synergistic effect. Methods:60 cases uremic patients with renal anemia selected as the research object, randomly divided into Shengxuening group and succinic acid ferrous group, 30 cases in each group. The patients of shengxuen-ing group were given oral Shengxuening tablets, and oral ferrous succinate group was given Ferrous Succinate Tablets. In accordance with the guidelines, the patients of 2 groups were given the recommended dose individ-ualized combination of erythropoietin treatment. After 16-weeks treatment, the clinical curative effect of the patients of 2 groups were observed and the changes of hemoglobin, hematocrit, serum ferritin and transferrin saturation were recorded before and after treatment in 2 groups. Meanwhile, the adverse reactions in the 2 groups were monitored. Results: After 16 weeks of treatment, the hemoglobin, hematocrit, serum ferritin, transferrin saturation of the 2 groups were increased compared with before treatment, the difference was statis-tically significant ( P < 0.05) . However, after treatment, the hemoglobin, hematocrit, serum ferritin, trans-ferrin saturation of Shengxuening group was significantly higher than that of ferrous succinate group, the differ-ence was statistically significant ( P < 0.05) . Compared with ferrous succinate group, Shengxuening group of adverse reaction is less. Conclusion: Compared with ferrous succinate group, Shengxuening can effectively supplement renal anemia in patients with uremia for iron, and less adverse reactions of blood safety.